Publications by authors named "Julia Nightingale"
Background: Most males with cystic fibrosis (mwCF) are infertile but with CF transmembrane conductance regulator (CFTR) modulator-conferred benefits, more are utilizing assisted reproductive technologies (ART). Administration of normal human doses of modulators in animal reproductive models caused no genotoxicity; no human data exists. Potential health decline following modulator discontinuation makes the decision to withhold therapy during reproduction challenging.
View Article and Find Full Text PDFArticle Synopsis
- - Daily inhaled therapy is crucial for maintaining lung health in people with cystic fibrosis (PwCF), but measuring adherence to therapy can be complicated due to varying treatment regimens among patients.
- - This study utilizes historical data from the UK CF Registry (2011-2015) to create a prediction rule for identifying current Psuedomonas aeruginosa (PA) status in PwCF, achieving high accuracy rates in predictions.
- - By effectively identifying patients with chronic PA infection using past registry data, the researchers aim to improve adherence monitoring and quality assessments of care across different medical centers.
Article Synopsis
- A study checked how much inhaled medicine people with cystic fibrosis (CF) received compared to how much they actually used.
- It found that many people had more medicine than they needed, leading to a waste of money—about £1,124 per person on average.
- The results show that people who didn't use their medicine as much wasted the most, suggesting that it's important to help people use their medicines properly.
Objectives: To undertake a process evaluation of an adherence support intervention for people with cystic fibrosis (PWCF), to assess its feasibility and acceptability.
Setting: Two UK cystic fibrosis (CF) units.
Participants: Fourteen adult PWCF; three professionals delivering adherence support ('interventionists'); five multi-disciplinary CF team members.
Background: Preventative medication reduces hospitalisations in people with cystic fibrosis (PWCF) but adherence is poor. We assessed the feasibility of a randomised controlled trial of a complex intervention, which combines display of real time adherence data and behaviour change techniques.
Methods: Design: Pilot, open-label, parallel-group RCT with concurrent semi-structured interviews.
Pseudomonas aeruginosa status influences cystic fibrosis (CF) clinical management but no 'gold standard' definition exists. The Leeds criteria are commonly used but may lack sensitivity for chronic P. aeruginosa.
View Article and Find Full Text PDFBackground: Outcome data for UK cystic fibrosis centres are publicly available in an annual report, which ranks centres by median FEV% predicted. We wished to assess whether there are differences in lung function outcomes between adult centres that might imply differing standards of care.
Methods: UK Registry data from 4761 subjects at 34 anonymised adult centres were used to calculate mean FEV% and rate of change of lung function for 2007-13.
Aerosol particle size influences airway drug deposition. Current inhaler devices are inefficient, delivering a heterodisperse distribution of drug particle sizes where, at best, 20% reaches the lungs. Monodisperse aerosols are the appropriate research tools to investigate basic aerosol science concepts within the human airways.
View Article and Find Full Text PDFThe aim of this study was to quantify lung oxidant stress after short-term ozone exposure as reflected by 8-isoprostane concentrations in exhaled breath condensate (EBC) and to investigate the effects of inhaled budesonide on this response. 8-Isoprostane is a prostaglandin-F(2 alpha) isomer that is formed in vivo by free radical-catalyzed peroxidation of arachidonic acid. EBC is a noninvasive method to collect airway secretions.
View Article and Find Full Text PDFStudy Objective: Several studies have demonstrated the superiority of salmeterol and formoterol to either regular treatment with albuterol or placebo. However, to date there have been no trials comparing the efficacy of salmeterol and formoterol in patients with severe asthma.
Design: We undertook a randomized, placebo-controlled, crossover study to compare 4 weeks of treatment with inhaled formoterol (12 microg twice daily) or salmeterol (50 microg twice daily) in patients with severe asthma whose conditions were not being adequately controlled by therapy with high doses of inhaled corticosteroids (i.